ZYBERNO
Stock Report
Updated Sep 1, 2026

CYTOSORBENTS CORPORATION (CTSO)

Healthcare • NASDAQ

$0.34

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
5.0/100
POOR BUSINESS
CYTOSORBENTS CORPORATION (CTSO) scores 5/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-445.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-34.7%)
Return on Capital (Capital Efficiency):CRITICAL (-37.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CYTOSORBENTS CORPORATION (CTSO) stock report — Zyberno Score 5/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CTSO generated -$10.25M in Owner Earnings. Capital was deployed as follows: $172.88K invested in capital expenditures. Reinvestment rate: 11.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.34
Market Cap:$21.42M

Valuation Multiples (2)

P/S Ratio:0.58x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$48.39M

Price Action & Momentum (3)

Momentum Percentile:3 / 100
% of 52-Week High:32.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-43.2%
Reinvestment Rate:11.0%
Fundamental Growth Rate (g):-4.1%

Margin Analysis (3)

Operating Margin Ttm:-34.7%
Net Margin Ttm:-48.9%
Ebitda Margin:-29.8%

TTM Performance (3)

Gross Margin Ttm:71.6%
Operating Margin Ttm:-34.7%
Net Margin Ttm:-48.9%

Yield Metrics (2)

Earnings Yield:-$72.52
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-219.1%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):0.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.66x
Quick Ratio:0.50x
Cash Ratio:0.18x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-8,286,000.00
Cash And Cash Equivalents:4,413,000.00
Long Term Debt:$17.24M
Net Debt:$26.98M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $37.22M
Linear Growth: 59.0%
📊 Click to view full CTSO Revenue analysis & methodology →
Cost Of Revenue Ttm:$10.57M

Profitability Breakdown (2)

Gross profit TTM: $26.65M
Linear Growth: 10.0%
📊 Click to view full CTSO Gross Profit analysis & methodology →
-$12.93M

Bottom Line Performance (3)

-$18.21M
Income Before Tax:-$16.96M
Ebitda Ttm:-11,075,792.00

Operating Expenses (5)

Operating Expenses:39,577,195.00
R And D Expense:5,848,848.00
Sga Expense:34,159,120.00
Income Tax Expense:-$401.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:60.7%
Sga To Revenue Percentage:354.6%
Ebitda Margin:-29.8%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$37.96M
Current Assets:$15.74M
Ppe Net:7,172,000.00
Goodwill:0.00
Intangible Assets:$2.86M

Liability Structure (4)

Total Liabilities:38,711,000.00
Current Liabilities:24,023,000.00
Long Term Debt:$17.24M
Short Term Debt:$14.15M

Equity & Capital (3)

Equity:-$751.00K
Retained Earnings:-$321.75M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:6,786,000.00
Inventory:3,686,000.00
Accounts Payable:2,002,000.00

Special Items (2)

Contract Liabilities:1,128,000.00
Stock Based Compensation:368,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$10.07M-$10.25M

Investment Activities (2)

Investing Cash Flow:-$46.00K
Capital Expenditures Ttm:172,879.00

Financing Activities (3)

Financing Cash Flow:$2.48M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$5.00M
Long Term Debt Repayments:$5.00M

Non-Cash Items (1)

Depreciation Amortization Ttm:1,853,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.29
-$0.29
Earnings Per Share Ttm:-$0.29

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.59
Operating Cash Flow Per Share:-$0.20

Book Value & Capital (2)

Book Value Per Share:-$0.01
Cash Per Share:0.07

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.88x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:5.48x
Days Sales Outstanding Ttm:66.55

Inventory Management (2)

Inventory Turnover Ttm:2.87x
Days Inventory Outstanding Ttm:127.32

Payables & Cash Cycle (2)

Days Payable Outstanding:69.15
Cash Conversion Cycle:124.72
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$10.25M

Damodaran Growth Analysis (2)

Reinvestment Rate:11.0%
Fundamental Growth Rate (g):-4.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):0.6%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):10.0%
Book Value Growth Rate (Linear):-44.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:CTSO
Company Name:CYTOSORBENTS CORPORATION
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:62.81M
Shares Outstanding Basic:62.81M
Shares Outstanding Diluted:62.81M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 09:27:16 UTC
Data Timestamp:2026-08-20T23:30:19.425381
Scroll to Top